SG10201807826XA - Novel full spectrum anti-dengue antibody - Google Patents

Novel full spectrum anti-dengue antibody

Info

Publication number
SG10201807826XA
SG10201807826XA SG10201807826XA SG10201807826XA SG10201807826XA SG 10201807826X A SG10201807826X A SG 10201807826XA SG 10201807826X A SG10201807826X A SG 10201807826XA SG 10201807826X A SG10201807826X A SG 10201807826XA SG 10201807826X A SG10201807826X A SG 10201807826XA
Authority
SG
Singapore
Prior art keywords
full spectrum
novel full
spectrum anti
antibody agents
antibody
Prior art date
Application number
SG10201807826XA
Other languages
English (en)
Inventor
Ram Sasisekharan
Kannan Tharakaraman
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of SG10201807826XA publication Critical patent/SG10201807826XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201807826XA 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody SG10201807826XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461938605P 2014-02-11 2014-02-11

Publications (1)

Publication Number Publication Date
SG10201807826XA true SG10201807826XA (en) 2018-10-30

Family

ID=53800606

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606163QA SG11201606163QA (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody
SG10201807826XA SG10201807826XA (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201606163QA SG11201606163QA (en) 2014-02-11 2015-02-11 Novel full spectrum anti-dengue antibody

Country Status (12)

Country Link
US (3) US9902764B2 (ru)
EP (1) EP3104888A4 (ru)
JP (1) JP6707455B2 (ru)
KR (1) KR20160119806A (ru)
CN (1) CN106413749B (ru)
AU (1) AU2015217149B2 (ru)
BR (1) BR112016017764A2 (ru)
CA (1) CA2938495A1 (ru)
IL (1) IL246788A0 (ru)
MX (1) MX2016009991A (ru)
SG (2) SG11201606163QA (ru)
WO (1) WO2015123362A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP2882453B1 (en) 2012-08-07 2021-01-06 Massachusetts Institute of Technology Anti-dengue virus antibodies and uses thereof
JP6764348B2 (ja) 2014-02-11 2020-09-30 ビステラ, インコーポレイテッド デングウイルスに対する抗体分子およびその使用
JP6707455B2 (ja) * 2014-02-11 2020-06-10 マサチューセッツ インスティテュート オブ テクノロジー 新規フルスペクトル抗デング抗体
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
TW202302144A (zh) 2016-03-25 2023-01-16 美商威特拉公司 登革病毒的抗體分子之配方設計
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2022008719A (ja) * 2016-11-23 2022-01-14 セルヴァス エーアイ インコーポレイテッド 疾患発症予測方法及び装置
GEP20237513B (en) 2016-12-23 2023-06-12 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
JP3801196B2 (ja) 1993-03-09 2006-07-26 ジェンザイム・コーポレイション 乳からの対象化合物の単離
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH07299655A (ja) 1994-04-30 1995-11-14 Aisin Seiki Co Ltd 内スプライン歯面仕上機
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US7927858B2 (en) 2002-11-01 2011-04-19 Glaxosmithkline Biologicals, S.A. Drying process
WO2005056600A2 (en) 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
BRPI0614265A2 (pt) 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
EP2653544A1 (en) 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
CA2738644A1 (en) 2008-10-05 2010-05-08 The Board Of Trustees Of The Leland Stanford Junior University Hepatitis c antibodies and uses thereof
CN102272155B (zh) * 2008-10-13 2018-05-25 生物医学研究所 登革热病毒中和抗体及其用途
KR20110097923A (ko) 2008-12-05 2011-08-31 엘파스, 인크. 항-지질 항체 결정 구조를 이용한 항체 설계
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
WO2013089647A1 (en) 2011-12-16 2013-06-20 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
WO2013173348A1 (en) * 2012-05-14 2013-11-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Cross-reactive antibodies against dengue virus and uses thereof
EP2882453B1 (en) * 2012-08-07 2021-01-06 Massachusetts Institute of Technology Anti-dengue virus antibodies and uses thereof
JP6707455B2 (ja) * 2014-02-11 2020-06-10 マサチューセッツ インスティテュート オブ テクノロジー 新規フルスペクトル抗デング抗体
JP6764348B2 (ja) * 2014-02-11 2020-09-30 ビステラ, インコーポレイテッド デングウイルスに対する抗体分子およびその使用

Also Published As

Publication number Publication date
KR20160119806A (ko) 2016-10-14
IL246788A0 (en) 2016-08-31
SG11201606163QA (en) 2016-08-30
US20180237504A1 (en) 2018-08-23
JP2017507131A (ja) 2017-03-16
EP3104888A1 (en) 2016-12-21
CN106413749B (zh) 2022-04-05
US11421018B2 (en) 2022-08-23
US20150368321A1 (en) 2015-12-24
AU2015217149B2 (en) 2020-09-10
CN106413749A (zh) 2017-02-15
US20200207841A1 (en) 2020-07-02
WO2015123362A1 (en) 2015-08-20
CA2938495A1 (en) 2015-08-20
AU2015217149A1 (en) 2016-09-08
US9902764B2 (en) 2018-02-27
MX2016009991A (es) 2016-10-07
EP3104888A4 (en) 2017-08-09
US10519220B2 (en) 2019-12-31
JP6707455B2 (ja) 2020-06-10
BR112016017764A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
MX2019008736A (es) Anticuerpos anti-virus del dengue y usos de los mismos.
SG10201807826XA (en) Novel full spectrum anti-dengue antibody
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
SA522431756B1 (ar) Tigit أجسام مضادة لـ
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MD4716C1 (ru) Антитела анти-LAG3 и антигенсвязывающие фрагменты
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
EA201890655A1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201791270A1 (ru) Модифицированные april-связывающие антитела
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
PH12016501366A1 (en) Novel anti-baff antibodies
PH12015501360A1 (en) Bmp-6 antibodies
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
MX2023009584A (es) Anticuerpos monoclonales anti-chinches y metodos de elaboracion y usos de los mismos.
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
MX2018009218A (es) Anticuerpos de cgrp y sus usos.